Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Prelude Therapeutics Inc PRLD

Healthcare Biotechnology
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789... see more

Recent & Breaking News (NDAQ:PRLD)

Prelude Therapeutics To Participate in Jefferies Healthcare Conference

GlobeNewswire May 31, 2023

Prelude Therapeutics Announces Pricing of Public Offering

GlobeNewswire May 18, 2023

Prelude Therapeutics Announces Launch of Proposed Public Offering

GlobeNewswire May 17, 2023

Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update

GlobeNewswire May 8, 2023

Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May

GlobeNewswire April 27, 2023

Prelude Therapeutics to Present at American Association for Cancer Research 2023 Conference

GlobeNewswire April 11, 2023

Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 15, 2023

Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers

GlobeNewswire March 15, 2023

Prelude Therapeutics To Participate in Barclays Global Healthcare Conference

GlobeNewswire March 1, 2023

Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences

GlobeNewswire February 9, 2023

Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 14, 2022

Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

GlobeNewswire October 18, 2022

Prelude Therapeutics To Participate in Upcoming HC Wainwright and Morgan Stanley Healthcare Conferences

GlobeNewswire September 6, 2022

Prelude Therapeutics Announces Second Quarter 2022 Financial Results and Business Update

GlobeNewswire August 9, 2022

Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update

GlobeNewswire May 10, 2022

Prelude Therapeutics Reports Full Year 2021 Financial Results

GlobeNewswire March 16, 2022

Prelude Therapeutics to Participate at the Barclays 2022 Global Healthcare Conference

GlobeNewswire March 11, 2022

Prelude Therapeutics Provides Clinical Update and Announces Presentation of New Preclinical Data at the Upcoming 2022 AACR Annual Meeting

GlobeNewswire March 9, 2022

Jane Huang, M.D., Joins Prelude Therapeutics as President and Chief Medical Officer

GlobeNewswire March 9, 2022

Prelude Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 11, 2022